**SMALL CELL**

**GO 300081**: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide with or Without Atezolizumab (Anti-PD-L1 Antibody) In Patients with Untreated Extensive Stage Small Cell Lung Cancer.


**NON-SMALL CELL**

**GO29527**: A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy in PD-L1-Selected Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer.


**A151216**: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Genetic Testing in screening patients with Stage IB-IIIA Non-Small Cell Lung Cancer That has been or will be removed by surgery.


**A081105**: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).


**E4512**: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

**1\(^{st}\) LINE ADVANCED AND OR RECURRENT NSCL**

14X-MC-JFCP: A Single-Arm, Multicenter, Open-Label, Phase 2 Study of nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy plus Necitumumab (LY3012211)(mAb) in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer


MK3475 PN 407: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)


**1\(^{st}\) LINE ADVANCED AND OR RECURRENT NSCL**

WP29158: A Phase 1b Study of the Safety and Pharmacology of MPDL3280A administered with Alectinib in Patients with Advanced Non-Small Cell Lung Cancer.


ML39237 BF1RST: A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics


**2\(^{nd}\) LINE ADVANCED OR RECURRENT NSCL**

54767414LUC2001: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer